Connect your AI

NewAmsterdam Pharma Company NAMS Net margin

Net margin at other companies

Merck & Co.MRK

13.6%-13.7pp

AmgenAMGN

21%+3.6pp

Regeneron PharmaceuticalsREGN

29.6%-2.3pp

Eli LillyLLY

35%+12.3pp

Denali Therapeutics Inc.DNLI

-33,121.9%-33,159pp

Other financials

Income statement

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

Market cap$3.67B+63.7%

Profitability

Operating margin-953.6%-3,536pp

FCF margin-630.1%-6,324pp

Returns & leverage

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Calculated from NewAmsterdam Pharma Company’s reported figures.

net income/total revenue=-942.8%

Based on trailing twelve months.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is NewAmsterdam Pharma Company's net margin?: NewAmsterdam Pharma Company (NAMS) reported net margin of -942.8% in Q1 2026.
How has NewAmsterdam Pharma Company's net margin changed year-over-year?: NewAmsterdam Pharma Company's net margin decreased by 137.2% year-over-year, from -397.5% to -942.8%.
What is the long-term trend for NewAmsterdam Pharma Company's net margin?: Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's net margin has grown at a 245.1% compound annual growth rate (CAGR), from -22% to -905.7%.
What does net margin mean?: Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.